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Summary
Objective: We are attempting to genetically-modify chondrocytes transplanted to cartilage in vitro as a prelude to gene
therapy trials in patients with osteoarthritis.
Design: With human cartilage and chondrocytes, we have explored the duration of binding of chondrocytes to
cartilage in vitro and the expression of the b-galactosidase gene introduced into the chondrocytes through infection
with an adenoviral vector both before and after transplant of the chondrocytes to cartilage.
Results: Transplanted chondrocytes continued to bind to cartilage explants at 45 days in our longest trial. We could
successfully infect chondrocytes with adenovirus at least 35 days after we transplanted the chondrocytes to cartilage.
Expression of the b-galactosidase gene continued throughout the duration of each trial.
Conclusions: These results raise the possibility of repairing and rebuilding cartilage by resurfacing the cartilage
with genetically modified chondrocytes. The ability to infect chondrocytes well after transplant raises the possibility
of repeated infections of surface chondrocytes as an alternative to repeated injections of chondrocytes into the joint
space.
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Introduction
Osteoarthritis (OA) is the most prevalent
chronic disorder affecting humans. This disease
places a huge economic burden on society and
often has severe adverse consequences for individ-
ual patients. The incidence of OA steadily
escalates with advancing age to become the most
prevalent disease adversely affecting quality of
life.
Despite the medical and economic consequences
of OA, therapies that can reverse the degenerative
changes that occur in articular cartilage and
restore cartilage to normal have not been
forthcoming. At present, all forms of treatment
including medical, physical and surgical ap-
proaches are focused on treating the symptoms of
the disease rather than on retarding or reversing
the OA disease process itself.
In the past decade there have been tremendous
advances in our understanding of the basic
pathologic processes that contribute to degener-
ation of articular cartilage. In healthy adult
cartilage chondrocytes maintain an equilibrium of
matrix synthesis and breakdown [1, 2]. Injury to
cartilage initiates a specific reparative process
that increases the production of proteoglycans and
collagen [2–9]. The absence of progressive break-
down results from a compensatory anabolic
response by chondrocytes to maintain normal
amounts of extracellular matrix despite increased
activities of matrix degrading enzymes [2, 8]. In
OA, the equilibrium between synthesis and loss of
matrix macromolecules is eventually lost in favour
of net catabolism and cartilage degeneration
ensues.
With improved understanding of these
fundamental mechanisms, there has been increas-
ing interest in evolving new therapeutic ap-
proaches that can repair or regenerate cartilage.
Potential therapeutic strategies for ‘healing’
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cartilage include decreasing chondrocytic
catabolic activity to prevent degeneration of
the constituent components of cartilage or
alternatively increasing the anabolic activity of
chondrocytes to promote cartilage repair.
In promoting anabolic activity, the production
of proteoglycans and collagen by native
chondrocytes can be increased. An alternative
or complementary strategy may be the
introduction of additional chondrocytes. In the
absence of these types of intervention, proteo-
glycan and collagen synthesis continue to rise in
response to increased cartilage catabolism until
the OA disease process is far advanced and
proteoglycan and collagen synthesis fall off
sharply.
The purpose of the present paper is to explore
the potential for combining these various
strategies in a multi-faceted attempt to
heal articular cartilage. To achieve this we
combined gene therapy approaches with cartilage
transplantation. The cartilage transplantation
allows for an increased population of chondrocytes
that can contribute to the healing of injured
articular cartilage. The introduction of gene
therapy may be used to either diminish
catabolic activity or increase anabolic activity
of both native chondrocytes and transplanted
chondrocytes. We believe that combining
these two approaches enhances the potential
to repair and resurface damaged articlar
cartilage.
Methods
cartilage organ culture and cultures of
human chondrocytes
Cartilage is taken from various patients with
osteoarthritis at the time of total knee
arthroplasty. The slices were washed in Gey’s
balanced salt solution and placed one slice per well
in 24-well flat bottom tissue culture plates. Organ
cultures are maintained in Dulbecco’s modified
Eagle’s medium (DMEM) with 10% fetal calf serum
(FCS) and the antibiotics penicillin, streptomycin,
and ciprofloxacin.
Cartilage is minced finely in Gey’s balanced salt
solution and the chondrocytes released from
cartilage by sequential digestion at 37° C for 1 h
with 2 mg/ml pronase (Boer Mann) followed by
1 mg/ml collagenase (Sigma) at 37° C overnight on
a gyratory shaker. Isolated chondrocytes
are centrifuged and washed three times in
PBS (500 g, 5 min, 20° C). The cells are seeded
at 2 · 105 cells/ml in DMEM containing 10% FCS
and the antibiotics penicillin, streptomycin, and
ciprofloxacin.
transplantation with infected chondrocytes
Chondrocytes are seeded at 105 cells/well in
six-well plates in DMEM containing 10% FCS and
antibiotics. When cells are 70% confluent, they are
washed twice with serum free DMEM and infected
with AdlacZ [10] diluted in serum free DMEM..
After 2 h at 37° C the cells are washed and cultured
in complete medium overnight. The following day
the chondrocytes are removed from the plate with
trypsin, placed into complete medium and added
slowly onto the articular surface of the cartilage
organ cultures. One-half to one million cells are
added to each 1 cm square piece of cartilage.
AdlacZ was provided by Dr Jeffrey M. Leiden at
the University of Chicago [10]. AdlacZ is an E1
and E3-deleted replication defective adenoviral
vector [10]. AdlacZ contains the b-galactosidase
gene driven by the b-actin promoter and the
cytomegalovirus enhancer [10].
transplantation with chondrocytes
before infection
Uninfected chondrocytes are transplanted to
cartilage organ culture (as above) and
subsequently infected with AdlacZ diluted in
serum free DMEM at a moi of 1000 pfu/cell. The
infection of the transplanted chondrocytes
was delayed for varying intervals of time as
noted in the text. Two hours after infection the
organ culture is washed and put into complete
medium.
detection of b-galactosidase expression
Chondrocytes or cartilage organ cultures were
washed three times in PBS and fixed for 5 min
at 4° C with 2% formaldehyde and 2%
glutaraldehyde in PBS. Samples were washed
in PBS and stained with 0.5 mg/ml bluo-gal in
PBS containing 5 mm potassium ferricyanide,
5 mm potassium ferrocyanide and 2 mm MgCl2.
Samples were incubated in the staining solution
for 14–24 h, and washed twice with PBS before
being examined by light microscopy. Bluo-gal
(halogenated indolyl-b-d-galactoside) is a
histochemical substrate for b-galactosidase that
produces a dark blue precipitate when hydrolyzed
by b-galactosidase.
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cultures in alginate beads
Alginate (Keltone LVCR, Monsanto) is a
negatively charged unsulfated copolymer of
l-guluronan and d-mannuronan that polymerizes
to form a gel in the presence of calcium ions or
other multivalent counterions [11]. We prepare
1.2% alginate in 150 mm NaCl with agitation. The
solution is heated to 50° C to reduce viscosity,
filtered through a 0.45 mm filter to sterilize and
cooled back to RT. The cells are encapsulated into
alginate beads in 24-well plates at nine beads per
well and 44 000 cells per bead. The chondrocytes
are suspended in the sterile, filtered low viscosity
alginate solution (1.2% in 150 mm NaCl), then
slowly in a dropwise fashion through a 22 gauge
needle dropped into excess 102 mm CaCl2 solution
in 24-well plates. The beads are allowed to gel for
10 min. The beads are washed four times in 0.15 m
NaCl and once in DMEM medium and then placed
in complete culture. Cells are released from
alginate beads by suspending the beads in three
volumes of 150 mm Na citrate and 0.15 m NaCl at
37° until the beads dissolve (about 15 min).
Thereleased cells are centrifuged at 2000 g for
5 min.
alcian blue staining
The cultures are fixed for 48 h in 2.5%
glutaraldehyde and simultaneously stained with
alcian blue 8GX using 0.05% alcian blue in 0.4m
MgCl2, 25 mm Sodium acetate (pH 5.6) [12]. Excess
stain is removed by washing in 3% acetic acid;
then 25 and 50% ethanol with 3% acetic acid and
finally 70% ethanol. The cultures are stored in 70%
ethanol.
Fm DiI labeling of chondrocytes
Chondrocytes are removed from culture with
trypsin and washed first with medium and then
three times with phosphate-buffered saline. A
stock solution of the Fm DiI (Molecular Probes;
50 mg DiI in 50 ml ethanol) is diluted 1:100 in
phosphate-buffered saline. The cells are incubated
with the diluted Fm DiI dye for 5 min at 37° C
followed by 15 min at 4° C. The cells are centrifuged
to remove excess dye before they are resuspended
in phosphate-buffered saline.
Results
We have established human cartilage organ
culture and cultures of human chondrocytes
allowing us to assess chondrocyte transplantation
to cartilage and gene transfer to chondrocytes as
a prelude to producing genetically modified
chondrocytes in vivo. The chondrocytes take on a
fibroblast-like appearance in monolayer culture.
This loss of phenotype is reversible as they readopt
a rounded morphology typical of chondrocytes and
produce proteoglycan when placed in a matrix
such as alginate beads [11, 13]. Fig. 1 shows
rounded human chondrocytes cultured in beads for
20 days before being released from the beads and
stained with alcian blue to detect proteoglycan
synthesis.
transplantation with infected chondrocytes
We have shown high efficiency of infection of
monolayers of human chondrocytes with the
adenoviral vector, AdlacZ that codes for
b-galactosidase. By staining with bluo gal we see
expression of the b-galactosidase gene by close to
100% of the chondrocytes. The predominantly
nuclear staining of cells growing in monolayer
culture is shown in Fig. 2. Uninfected
chondrocytes do not give any background staining
(data not shown).
Human chondrocytes were infected with AdlacZ
before being transplanted to organ culture.
Previous studies showed that transplanted
chondrocytes adhered to cartilage in organ culture
[14] or to focal articular cartilage defects in vivo in
rabbits [15, 16] and continued to express
transfected genes up to the 10 [15] or 28 [16]
days tested. In this study we stained the tissue
for b-galactosidase activity at varying time
points after transplant to determine if the
transplanted chondrocytes survived and the
b-galactosidase gene introduced with the
adenoviral vector, AdlacZ, continued to be
expressed. The chondrocytes continued to express
b-galactosidase for the duration of the trial 14 days
after transplanting cells infected with AdlacZ
(Table I). We have also shown that human
chondrocytes will bind to cartilage in organ
culture using fluorescently-labeled cells. We
labeled chondrocytes with the membrane dye Fm
DiI (Molecular Probes), and allowed the
chondrocytes to adhere to cartilage. With this
approach we have shown that the chondrocytes
adhere to the cartilage for at least 28 days
(Table I).
transplanting human chondrocytes before
infection with AdlacZ
Human chondrocytes were infected with
AdlacZ after being transplanted to organ culture.
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Fig. 1. Human chondrocytes were cultured in alginate
beads for 20 days. The cells were released using sodium
citrate to chelate the calcium ions and to dissolve the
beads. The clustered cells were subsequently stained
with alcian blue to detect proteoglycan.
Fig. 2. Human chondrocytes were infected with
the adenoviral vector, AdlacZ, that codes for
b-galactosidase. The cultures were subsequently
stained with bluo gal we see expression of the
b-galactosidase gene. The staining is predominantly
nuclear.
The tissue was stained for b-galactosidase
activity at varying time points after that to
establish if the transplanted chondrocytes
survived and the b-galactosidase gene introduced
with the adenoviral vector, AdlacZ, continued
to be expressed for the duration of the trial
29 days after transplant and 27 days after
infection of chondrocytes following transplant
(Table I). Fig. 3(a)–(c) show expression 6, 20
and 27 days after infection. Transplant was
2 days before infection in each case. Direct
infection with AdlacZ of cartilage with no prior
repopulation with cultured chondrocytes results
in very few blue foci compared to other trials
where the cartilage was resurfaced [Fig. 3(d)].
This is likely a consequence of the extracellular
matrix of cartilage that would exclude penetration
of the virus to endogenous chondrocytes. It is
necessary first to repopulate the surface of the
cartilage with infected chondrocytes or to infect
the chondrocytes subsequent to repopulating the
surface of the cartilage.
delayed infection of transplanted human
chondrocytes with AdlacZ
We have transplanted human chondrocytes to
cartilage and then delayed infection to establish if
the chondrocytes remain close enough to the
surface to remain accessible to virus perhaps
allowing for a repeat infection in vivo (Table I).
The chondrocytes were infected as late as 35
Table I
Week 1 Week 2 Week 3 Week 4 Week 7
Preinfected or prestained*
chondrocytes + † + † + * N.D. N.D.
Infected 2 days following
transplant + + + + N.D.
Infection at variable times
following transplant + + + + +
"a# Chondrocytes were infected with adenovirus AdlacZ "$# or stained with the ~uorescent dye Fm DiI
"# prior to transplantation and analyzed for b!galactosidase activity or ~uorescence on cartilage at variable
times after transplant[
"b# Chondrocytes were infected with adenovirus AdlacZ 1 days after transplantation and analyzed for
b!galactosidase activity at variable times after transplant[
"c# The adenovirus\ AdlacZ was used to infect endogenous chondrocytes in cartilage without prior
transplant of chondrocytes from tissue culture[
"d# Chondrocytes were infected with adenovirus AdlacZ at variable times after transplantation and
subsequently analyzed for b!galactosidase activity[
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Fig. 3. Human chondrocytes were infected with AdlacZ 2 days after being transplanted to organ culture. The tissue
was stained for b-galactosidase activity at (a) 6, (b) 20 and (c) 27 days after infection. As a control cartilage was infected
with AdlacZ with no prior repopulation with cultured chondrocytes and the tissue was stained for b-galactosidase
activity (d).
days after transplant and b-galactosidase
activity determined at 45 days (Fig. 4). The
ability to infect chondrocytes after transplant
raises the possibility of repeated infections
of surface chondrocytes as an alternative to
repeated injections of chondrocytes into the joint
space.
Discussion
Our goal is to deliver chondroprotective genes
directly to the chondrocytes in cartilage. In this
way we hope to re-establish the equilibrium
between matrix synthesis and breakdown. This
should both repair damaged cartilage and extend
the life of hypermetabolic chondrocytes attempting
to maintain the extracellular matrix. As a prelude
to gene therapy trials in patients with
osteoarthritis we have explored the persistence of
binding of transplanted chondrocytes to cartilage
in vitro and the expression of the b-galactosidase
gene introduced into the chondrocytes before and
after transplant of the chondrocytes to cartilage.
Establishment of cartilage organ culture from
human cartilage allows for assessment of
chondrocyte transplantation to cartilage and gene
transfer to chondrocytes as a prelude to producing
genetically modified chondrocytes in vivo. We
have shown that human chondrocytes will bind
to cartilage in organ culture using
fluorescently-labeled cells. We labeled
chondrocytes with the membrane dye Fm DiI
(Molecular Probes), and allowed the chondrocytes
Fig. 4. Human chondrocytes were transplanted to
cartilage in organ culture and infected with AdlacZ 35
days later. The b-galactosidase activity was determined
10 days after infection.
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to adhere to cartilage. We have shown with this
analysis that the chondrocytes adhere to the
cartilage for at least 28 days. We have shown that
these chondrocytes remain viable on the surface
of the cartilage as they continue to express the
b-galactosidase gene. We initially infect the
chondrocytes with adenovirus coding for
the b-galactosidase gene. Transplantation of the
infected chondrocytes to cartilage results in
the continued stable expression of the
b-galactosidase gene out to 14 days tested to date.
Chondrocytes infected with AdlacZ 2 days after
being transplanted to organ culture continued to
express b-galactosidase 29 days after transplant
and 27 days after infection of chondrocytes
following transplant [Fig. 3(c)]. Chondrocytes
that can adopt a fibroblast-like appearance in
culture readopt a round and cuboidal shape
typical of chondrocytes when attached to
cartilage [17]. The transplanted chondrocytes will
synthesize new matrix and integrate into the
cartilage [14].
We have also transplanted unmodified
chondrocytes to cartilage and shown that the
transplanted chondrocytes can be efficiently
infected well after the transplant (Fig. 4). We can
infect the chondrocytes as late as 35 days after
transplant suggesting that repeated infections
instead of repeated chondrocyte transplants may
be feasible. Direct infection of chondrocytes in
cartilage without prior transplantation gives
many fewer infected cells. Our results may indicate
that the matrix synthesized by these cells over
the short term is not sufficient to block infection
by adenovirus through steric hindrance It is
also possible that the transplanted cells are more
easily infected than endogenous chondrocytes as a
result of a different profile of cell surface
receptors. In either case it is necessary first to
repopulate the surface of the cartilage with
infected chondrocytes or to infect the
chondrocytes after repopulating the surface of the
cartilage.
We are attempting to combine gene therapy
approaches with cartilage transplantation. The
introduction of new gene products has the
potential to both decrease catabolic and increase
anabolic activity of transplanted chondrocytes and
chondrocytes native to the cartilage. The cartilage
transplantation itself provides an increased
population of chondrocytes that can contribute to
healing injured articular cartilage. The
combination of these methods should enhance
efforts to resurface and repair degenerated
articular cartilage.
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